Imran Alibhai

Houston Methodist Sugar Land Hospital — United States

Medicine · Health Sciences

9h-index864citations27works2.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(14), HER2/EGFR in Cancer Research(12), Chronic Lymphocytic Leukemia Research(9), Cytokine Signaling Pathways and Interactions(6), Neurotransmitter Receptor Influence on Behavior(4)

Publications27 total

Supplementary File S1 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
2025· 1 citedOpen Access
Supplementary Table S1 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
2025Open Access
Abstract 5843: Selective small molecule inhibitor of STAT3 suppresses tumor growth and improves immune checkpoint inhibitor efficacy in <i>KRAS</i> mutant lung cancer
Cancer Research·2025
Data from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Table S1 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
2025Open Access
Table 2 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
2025Open Access
Table 3 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
2025Open Access
Table 1 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
2025· 1 citedOpen Access
Supplementary File S1 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
2025Open Access
Figure 2 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
2025Open Access
Table 4 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
2025Open Access
Figure 1 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
2025Open Access
Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
Clinical Cancer Research·2025· 28 citedOpen Access
REVERT-IPF STUDY: FROM PRECLINICAL POC TO ACTIVELY ENROLLING CLINICAL TRIAL TARGETING THE SINGULAR NODE IN FIBROSIS WITH TTI-101, AN INHIBITOR OF STAT3
CHEST Journal·2024Open Access
A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.
Journal of Clinical Oncology·2024· 1 cited
Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.
Journal of Clinical Oncology·2023· 14 cited
First-in-man phase I clinical trial evaluating TTI-101, an orally bioavailable, small molecule inhibitor of STAT3, in patients with advanced solid tumors.
Journal of Clinical Oncology·2021· 8 cited
Striatal regulation of ΔFosB, FosB, and cFos during cocaine self‐administration and withdrawal
Journal of Neurochemistry·2010· 82 citedOpen Access
Table of Contents
Biological Psychiatry·2009Open Access
Environmental Enrichment Produces a Behavioral Phenotype Mediated by Low Cyclic Adenosine Monophosphate Response Element Binding (CREB) Activity in the Nucleus Accumbens
Biological Psychiatry·2009· 175 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Sofia de Achaval(17), Ahmed O. Kaseb(15), Apostolia M. Tsimberidou(14), John Kauh(14), David J. Tweardy(14), David Vining(13), Sukeshi Patel Arora(13), Carrie Cartwright(13), Rony Avritscher(13), Jeffrey Larson(12), Eric J. Nestler(9), Thomas A. Green(4), Arvind Kumar(3), Stephen Unterberg(3), Danielle Graham(3), Rachael L. Neve(3), Tiffany Carle(2), C. Nathaniel Roybal(2), Catharine A. Winstanley(2), David E. H. Theobald(2)